Xenon MRI in the News

Xenon Imaging Expanded Indication to Include Children 6 Years and Older - June 2nd, 2025

The FDA has approved Polarean’s Supplemental New Drug Application to expand the indication of XENOVIEW. This approval immediately lowers the minimum patient age from 12 to 6 years old, significantly broadening access to this technology.

Research at St. Paul’s Hospital Uncovers Cause of Lung Long COVID - April 1st, 2025

A research team led by HLI Director, Dr. Don Sin, used xenon MRI, an advanced imaging technology, and single-cell sequencing of lung samples, supported by the HLI’s biobank team, to uncover the underlying mechanism behind persistent respiratory symptoms in long COVID patients.

University of Missouri Pioneer a New Diagnostic Tool for Respiratory Diseases - November 29th, 2023

At the University of Missouri, FDA approved Xe MRI will help doctors and patients make better decisions more quickly about which treatments to try, and whether those treatments are having the intended effect, leading to better results for patients and saving time and money.

Cincinnati Children’s Images First Clinical Patient in North America Using Novel Xenon Gas - May 11th, 2023

Cincinnati Children’s Hospital Medical Center has become the first hospital in the nation to image a patient with Xe MRI that enables a safe and detailed view of lung ventilation, since its FDA approval for ages 12 and older in December of 2022.

FDA Approves Polarean’s XENOVIEW™ for use with MRI for the evaluation of lung ventilation - December 28th, 2022

Polarean Imaging, the medical imaging technology company, announces that the U.S. Food and Drug Administration has granted approval for its drug device combination product, XENOVIEW.
XENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (“MRI”) for evaluation of lung ventilation in adults and
pediatric patients aged 12 years and older.